Characteristics of study subjects who received adjuvant chemotherapy, by province
| CHARACTERISTIC | BRITISH COLUMBIA, 2007 TO 2011, N (%)* (N = 4133) | MANITOBA, 2007 TO 2012, N (%)* (N = 1472) | ONTARIO, 2007 TO 2011, N (%)* (N = 12 851) |
|---|---|---|---|
| Age group, y | |||
| • < 40 | 276 (6.7) | 130 (8.8) | 1299 (10.1) |
| • 40–49 | 1157 (28.0) | 405 (27.5) | 3302 (25.7) |
| • 50–59 | 1412 (34.2) | 514 (34.9) | 4252 (33.1) |
| • 60–69 | 1019 (24.7) | 325 (22.1) | 3059 (23.8) |
| • 70–74 | 189 (4.6) | 68 (4.6) | 610 (4.7) |
| • > 74 | 80 (1.9) | 30 (2.0) | 329 (2.6) |
| Comorbidity, ADGs | |||
| • 0–3 | 1534 (37.1) | 406 (27.6) | 3584 (27.9) |
| • 4–5 | 1092 (26.4) | 346 (23.5) | 3126 (24.3) |
| • 6–7 | 746 (18.0) | 317 (21.5) | 2832 (22.0) |
| • 8–9 | 472 (11.4) | 204 (13.9) | 1831 (14.2) |
| • ≥ 10 | 284 (6.9) | 199 (13.5) | 1478 (11.5) |
| • Unknown | 5 (0.1) | 0 (0.0) | 0 (0.0) |
| Stage at diagnosis | |||
| • I | 1083 (26.2) | 344 (23.4) | 2881 (22.4) |
| • II | 2182 (52.8) | 775 (52.6) | 7332 (57.1) |
| • III | 868 (21.0) | 353 (24.0) | 2638 (20.5) |
ADG—Johns Hopkins Aggregated Diagnosis Group.
↵* Percentages might not add to 100 owing to rounding.